fashion -WSS

fashion

author：focus 2025-08-08 08:10:13 - browse：697

Adam's take main illustration — Molly Ferguson/STAT

Have you heard the news? I’m launching a weekly email newsletter starting on March 28. It’s called Adam’s Biotech Scorecard and it’s exclusively for STAT subscribers. One catch: We need you to sign up, which you can do here. What should you expect to see in my newsletter each week? Unfiltered, uncompromising, and (hopefully) valuable insight and analysis from the intersection of Wall Street and biotech. Plus, a few dashes of fun.

This week: A chat with Argenx CEO Tim Van Hauwermeiren, and updates on biotech PIPEs, Madrigal Pharmaceuticals, and Annovis Bio.

The Belgian drugmaker Argenx is preparing for a commercial launch this summer that will expand the use of its IgG-lowering antibody Vyvgart to patients with chronic inflammatory demyelinating polyneuropathy, or CIDP, an autoimmune nerve disorder that causes people to lose feeling and muscle strength in the arms and legs.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Cancer cells are shown to suck energy source from immune cells

WSS

Massive project maps cells in human brain in unprecedented detail

CZI to create biohub to build anti

STAT Summit: Ending the crisis of Black deaths in the U.S.

How doctors and nurses shape Google's AI

European regulators recommend Amylyx's ALS drug be rejected

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

hotspot

fashion

focus

Cancer drug shortages should be causing more outrage

Health tech investors get more selective as pandemic boom fades

United colonoscopy coverage change 'may cost lives,' doctors say

STAT Summit: Meghan O’Rourke on making chronic illness visible

George Santos makes 1st court appearance after pleading not guilty to 13 counts

The problems with dementia villages

Medicare details structure of new drug price negotiation program

Results on Novartis prostate cancer therapy could expand its use

Guidelines to prevent youth baseball injuries need more muscle

European regulators recommend Amylyx's ALS drug be rejected

explore

Why a market frenzy over new weight loss drugs defies logic

ADCs take center stage as promising cancer treatments

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

UnitedHealth, Optum discontinue NaviHealth name

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Nick Jonas talks about managing diabetes along with his career

leisure time

entertainment

knowledge

hotspot